Dizziness

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

Retrieved on: 
Thursday, December 14, 2023
Health, FDA, Consumer, Women, Clinical Trials, Pharmaceutical, Biotechnology, CNS, Capsule, Woman, Tell, Medicaid, Behavior, Hope, Therapy, Breast milk, Grammatical mood, Physician, Risk, New America (organization), Patient, Multimedia, Insurance, Pregnancy, CIV, Theft, Medical research, Benzodiazepine, Vitamin, Diagnosis, BIIB, PPD, Mental health, Central nervous system, Alertness, Confusion, Walking, Somnolence, OBGYN, Dizziness, Pharmacy, Dietary supplement, Pharmaceutical industry, Nursing, Birth control, Liquor, Gasoline, Health insurance, Hospital, Sage, Biogen

View the full release here: https://www.businesswire.com/news/home/20231213368658/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231213368658/en/
    “For women with PPD, delayed improvement in depressive symptoms can significantly worsen outcomes.
  • The program also includes financial assistance, such as a copay assistance program, and product at no cost for eligible patients.
  • The companies are partnering with several of the leading national specialty pharmacies and ZURZUVAE will be shipped directly to women with PPD who are prescribed the treatment.
  • ZURZUVAE is not for use in children
    How can I watch for and try to prevent suicidal thoughts and actions?

MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cough, FACP, Spleen, PST, Food, European Medicines Agency, JAK, GMT, ASH, Headache, Plasma, Disease, Constipation, IL-6, Fatigue, MorphoSys, Patient, Thrombocytopenia, CET, Periodic breathing, Weakness, COVID-19, Prognosis, Diarrhea, Nausea, Survival, EST, Dysgeusia, TNF, Anemia, Fibrosis, Ruxolitinib, BET, Bone marrow, Dizziness, Vaccine, Dietary supplement, Medical imaging

Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.

Key Points: 
  • Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.
  • Increased cytokine levels are associated with all four disease hallmarks; increased IL-8 levels are also associated with worse survival outcomes.
  • Discontinuation rates due to adverse events were 10.7% with pelabresib and ruxolitinib and 6.5% with placebo plus ruxolitinib.
  • “The four hallmarks of myelofibrosis – enlarged spleen, anemia, bone marrow fibrosis and disease-associated symptoms – have a strong impact on a patient’s life.

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

Retrieved on: 
Thursday, December 7, 2023
Health, Neurology, General Health, Research, Pharmaceutical, Science, COMT, Medicine, Capsule, Sleep, Aggression, BIAL, Brain, Behavior, NYSE, Hormone, Senior, Food, Parkinson's disease, Eating, Movement, Gambling, Liver, PD, Delusion, Hallucination, Constipation, Sleep disorder, Patient, Multimedia, Dopamine, Dobutamine, Carbidopa, Behavior informatics, FDA, Isocarboxazid, Isoprenaline, Catecholamine, Vitamin, Partnership, Norepinephrine, Carbidopa/levodopa, Adrenaline, L-DOPA, Phenelzine, Mouth, Hearing, Physician, Neoplasm, Dyskinesia, Medication, Somnolence, Accident, Dizziness, Tranylcypromine, Weight loss, Psychosis, Pharmaceutical industry, Birth control, S.A, Amneal Pharmaceuticals, LD

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.
  • Carbidopa/levodopa (CD/LD), which works to control the symptoms of PD, has been the gold-standard treatment for PD since the 1970s.
  • ONGENTYS® works by inhibiting the COMT enzyme – which breaks down LD – making more LD available to reach the brain, thereby reducing “Off” time.
  • The financial terms of the agreement were not disclosed, and any incremental expenses associated with this product are contemplated within Amneal’s guidance.

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Retrieved on: 
Thursday, November 9, 2023
FDA, Health, Genetics, General Health, Pharmaceutical, Biotechnology, Migraine, Safety, Ohio State University, Toll, Food, Incidence, Abdominal pain, Upper respiratory tract infection, Headache, TTP, Disease, Hematology, Mortality, Internal medicine, Thrombotic thrombocytopenic purpura, Patient, Thrombocytopenia, Microangiopathic hemolytic anemia, Diarrhea, Nausea, Thrombotic microangiopathy, Dizziness, Vaccine, Pharmaceutical industry, ADAMTS13, Takeda

Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).
  • “As we strive to help patients with limited or no treatment options, developing innovative treatments in rare diseases is an inspiring challenge and one we have taken on for 70-plus years as a leader in hematology.
  • “ADZYNMA provides patients with a treatment option that replaces their deficient ADAMTS13 enzyme and offers a favorable efficacy and safety profile and reduced administration time and volume compared to current plasma-based therapies.
  • ADZYNMA is a recombinant form of the ADAMTS13 protein.

Ubie's AI Symptom Checker Used by 2 Million Americans in First Year, Fueling Pharma Partnerships

Retrieved on: 
Monday, December 4, 2023
Pulmonary fibrosis, Synthetic media, Boehringer Ingelheim, Collection, Traction, Patient, Documentation, Health, Lung cancer, Multiple sclerosis, Diagnosis, Press release, Dizziness, Pharmaceutical industry, Medical device, Dietary supplement, Pfizer, Takeda, Audi Q5

NEW YORK, Dec. 4, 2023 /PRNewswire/ -- Ubie, a forerunner in the digital health arena, proudly announces a notable achievement that underscores its commitment to revolutionizing healthcare: Ubie's AI Symptom Checker has been used more than 2 million times in the U.S. since its introduction to the market just over a year ago. This milestone demonstrates the significant traction the tool has gained among individuals eager to better understand and manage their health.

Key Points: 
  • Ubie, a trailblazing AI-driven healthcare company, has achieved a new milestone with its AI Symptom Checker, surpassing 2 million uses in the U.S. in just over a year.
  • Leveraging this expanding user engagement, Ubie is advancing its partnerships with pharmaceutical companies to promote early disease detection and treatment.
  • This milestone demonstrates the significant traction the tool has gained among individuals eager to better understand and manage their health.
  • For more information about Ubie and its AI Symptom Checker, please visit Ubie AI Symptom Checker .

Environmental Sensor Market worth $3.0 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, November 17, 2023
Carbon, VOC, Climate change, Carbon dioxide, Investment, Ecosystem, Carbon monoxide, Home appliance, Oxygen, Region, Growth, Volatile organic compound, HVAC, Car, Raritan Inc., Internet of things, Headache, Communication, Nausea, Amphenol, Dizziness, Schneider Electric, UV, Honeywell, Weather, OTDR, Omron, MEMS, Image sensor, Research, Electronics, Tablet, Switch, Texas Instruments, Humidity, Biophysical environment, Pressure sensor, Ams-OSRAM, Consumer electronics, Hydrocarbon, Infrared, Geography, Application, Temperature, Thermistor, Motion, Pressure

By type, the gas/air quality segment is projected to grow at high CAGR of the environmental sensor market during the forecast period.

Key Points: 
  • By type, the gas/air quality segment is projected to grow at high CAGR of the environmental sensor market during the forecast period.
  • Consumer electronics segment is projected to grow at high CAGR of the environmental sensor market during the forecast period.
  • The consumer electronics segment is expected to grow at a high CAGR in the environmental sensor market during the forecast period.
  • Noth America is poised for significant growth in the environmental sensor market by 2028.

Environmental Sensor Market worth $3.0 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, November 17, 2023
Carbon, VOC, Climate change, Carbon dioxide, Investment, Ecosystem, Carbon monoxide, Home appliance, Oxygen, Region, Growth, Volatile organic compound, HVAC, Car, Raritan Inc., Internet of things, Headache, Communication, Nausea, Amphenol, Dizziness, Schneider Electric, UV, Honeywell, Weather, OTDR, Omron, MEMS, Image sensor, Research, Electronics, Tablet, Switch, Texas Instruments, Humidity, Biophysical environment, Pressure sensor, Ams-OSRAM, Consumer electronics, Hydrocarbon, Infrared, Geography, Application, Temperature, Thermistor, Motion, Pressure

By type, the gas/air quality segment is projected to grow at high CAGR of the environmental sensor market during the forecast period.

Key Points: 
  • By type, the gas/air quality segment is projected to grow at high CAGR of the environmental sensor market during the forecast period.
  • Consumer electronics segment is projected to grow at high CAGR of the environmental sensor market during the forecast period.
  • The consumer electronics segment is expected to grow at a high CAGR in the environmental sensor market during the forecast period.
  • Noth America is poised for significant growth in the environmental sensor market by 2028.

RayNeo Air 2 XR Glasses Revolutionize Wearable Display User Experience, Launched on Amazon US

Retrieved on: 
Thursday, November 9, 2023
Steam Deck, Nose, Sale, PPD, TCL, PlayStation, Temperature, SRGB, Pressure, Face, FOV, Dizziness, News, Xbox, Nintendo Switch, Sony, Immersion, Environment, MTF, XR, Privacy, MicroLED, RRP, Amazon, Anxiety, AR, Personal computer, Flicker-free, 1080p, Video game, Telescopic sight, Television, Online shopping

The RayNeo Air 2 marks RayNeo's latest achievement in consumer-focused wearable displays, following the groundbreaking success of the RayNeo X2 true AR glasses -- the world's first binocular full-color MicroLED optical waveguide AR glasses.

Key Points: 
  • IRVINE, Calif., Nov. 8, 2023 /PRNewswire/ -- RayNeo™, an industry leader in consumer-grade augmented reality (AR) innovation, has launched its latest RayNeo Air 2 XR glasses for the global markets.
  • The RayNeo Air 2 marks RayNeo's latest achievement in consumer-focused wearable displays, following the groundbreaking success of the RayNeo X2 true AR glasses -- the world's first binocular full-color MicroLED optical waveguide AR glasses.
  • Riding the wave of display breakthroughs, the RayNeo Air 2 aims to enhance the holistic user experience of XR wearables.
  • Recognizing valuable feedback from our users, RayNeo has incorporated a personal touch to the latest RayNeo Air 2 glasses.

The TBI Action Alliance Brings Together a Passionate Community to Expedite Accurate Diagnosis and Treatments for Those Suffering from Traumatic Brain Injury

Retrieved on: 
Wednesday, November 8, 2023
TBI, Alzheimer's disease, FDA, Research, Veterans Health Administration, Chronic traumatic encephalopathy, CTE, International, Headache, Prevalence, Head injury, Dizziness, Organization, Veteran, Doctor of Philosophy, Sleep, Athlete, Brain, Caregiver, Division, Risk, Doctor of Science, Parkinson's disease, Community, Woman, DMD, Anxiety, Patient, Traumatic brain injury, Memory, Injury, Joint Planning and Development Office, National Association, Pharmaceutical industry, Neuroscience, CVB, MD, Medicine

NEW YORK, Nov. 8, 2023 /PRNewswire/ -- The TBI Action Alliance (TBIAA) today announced the first-ever large-scale coordinated effort to accelerate the development of accurate diagnostics and treatments to improve the lives of the more than 5.3 million people living with TBI-related symptoms. Founded by Cohen Veterans Bioscience (CVB) with more than 20 organizations including partners such as American Brain Coalition, National Association of Veterans' Research and Education Foundations, National Association of State Head Injury Administrators, National TBI Registry Coalition and PINK Concussions, the Alliance has come together to provide solutions to this widespread and significantly under-addressed public health crisis.

Key Points: 
  • On November 9, The TBI Action Alliance will hold its inaugural meeting in Washington DC to share and discuss its plan to address the TBI public health crisis.
  • Contributors such as Rachel Ramoni, DMD, ScD, Chief Research & Development Officer, Veterans Health Administration will provide a historical perspective and what is needed on the path ahead.
  • "Traumatic Brain Injury due to head trauma affects everyone and often devastates the lives of those affected.
  • The high prevalence of TBI creates significant impact on patients, caregivers, the health care system, and society as a whole.

World's First Dual-Chamber Leadless Pacemaker Now Available for Patients with Abnormally Slow Heart Rhythm

Retrieved on: 
Tuesday, November 7, 2023
Patient, Research, VR, MedSTAR, Society of Thoracic Surgeons, Heart, Vein, MD, AAA, Dizziness, Skin, Burn center, Cardiac electrophysiology, Inflammation, Ambulance, Observation, Cardiology, Multimedia, Quality of life, Joint Commission, Clinical trial, Pulse, Risk, Thigh, Teaching, Hospital, Blood, Society, Fatigue, Medical device, MedStar Washington Hospital Center

WASHINGTON, Nov. 7, 2023 /PRNewswire/ -- MedStar Washington Hospital Center is one of a select few institutions nationwide now offering patients with abnormally slow heart rates breakthrough technology that delivers treatment by a revolutionary new technology: two tiny leadless pacemakers implanted within the heart.

Key Points: 
  • On Monday, Nov. 6, the heart rhythm team at MedStar Washington implanted the Washington region's first approved leadless dual-chamber pacing device in two patients.
  • Their procedures went well and both patients stayed overnight for observation and are now resting at home.
  • "The leadless dual-chamber pacemaker is an excellent option to treat abnormally slow heart rates," said Cardiac Electrophysiologist Cyrus Hadadi, MD , associate director of Cardiac Arrhythmia Research at MedStar Washington Hospital Center.
  • Most patients needing pacemaker therapy require dual-chamber systems to best regulate their rhythm, and this requires an information exchange between both heart chambers.